Key Points
- Director Craig Mull purchased 20,000 Cipher Pharmaceuticals shares at an average price of C$14.16, investing C$283,200 and increasing his direct ownership by 2.02% to 1,009,953 shares.
- Cipher Pharmaceuticals shares opened at C$14.53, with a market capitalization of approximately C$369.3 million and a 12-month trading range of C$12.48 to C$20.56.
- The company reported quarterly EPS of C$0.21 on revenue of C$17.14 million, alongside a 58.81% net margin and 22.74% return on equity.
Cipher Pharmaceuticals Inc. (TSE:CPH - Get Free Report) (NASDAQ:CPHR) Director Craig Mull acquired 20,000 shares of the stock in a transaction dated Friday, September 18th. The stock was acquired at an average cost of C$14.16 per share, for a total transaction of C$283,200.00. Following the purchase, the director directly owned 1,009,953 shares in the company, valued at approximately C$14,300,934.48. The trade was a 2.02% increase in their ownership of the stock.
Cipher Pharmaceuticals Stock Up 0.8%
TSE CPH opened at C$14.53 on Wednesday. Cipher Pharmaceuticals Inc. has a 12 month low of C$12.48 and a 12 month high of C$20.56. The company has a market capitalization of C$369.28 million, a P/E ratio of 12.97 and a beta of 1.05. The company's 50 day simple moving average is C$15.29 and its 200 day simple moving average is C$16.51. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.59 and a quick ratio of 2.67.
Cipher Pharmaceuticals (TSE:CPH - Get Free Report) (NASDAQ:CPHR) last posted its quarterly earnings results on Tuesday, August 11th. The company reported C$0.21 earnings per share (EPS) for the quarter. The firm had revenue of C$17.14 million for the quarter. Cipher Pharmaceuticals had a net margin of 58.81% and a return on equity of 22.74%. Equities research analysts expect that Cipher Pharmaceuticals Inc. will post 1.2907348 earnings per share for the current fiscal year.
Cipher Pharmaceuticals Company Profile
(
Get Free Report)
Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
